seroquel prolong forðatafla 300 mg
cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 300 mg
seroquel prolong forðatafla 200 mg
cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 200 mg
seroquel prolong forðatafla 150 mg
cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 150 mg
somakit toc
advanced accelerator applications - edotreótíð - neuroendocrine tumors; radionuclide imaging - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. eftir radiolabelling með gallín (68ga) i lausn, lausn gallín (68ga) edotreotide fæst er ætlað fyrir sneiðmyndatöku losun höfði (gÆludÝr) hugsanlegur somatostatini viðtaka yfirtjáningu í fullorðinn sjúklinga með staðfest eða grun vel þroskað maga-enteropancreatic taugakirtilsuppruna æxli (gep-hrein) fyrir localizing aðal æxli og þeirra meinvörp.
locametz
novartis europharm limited - gozetotide - radionuclide imaging - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - stækkun Æxli, gelding-Þola - heilsueyðandi lyf - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
dipentum tafla 500 mg
atnahs pharma netherlands b.v. - olsalazinum natríum - tafla - 500 mg
dipentum hart hylki 250 mg
atnahs pharma netherlands b.v. - olsalazinum natríum - hart hylki - 250 mg
postinor tafla 1,5 mg
gedeon richter plc.* - levonorgestrelum inn - tafla - 1,5 mg
cyclogest leggangastíll 400 mg
gedeon richter plc.* - progesteronum inn - leggangastíll - 400 mg